SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.

Shandong Buchang Pharmaceuticals Co., Ltd.

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-07-09			5-day change	1st Jan Change
16.57 ^CNY	+0.18%		+1.66%	+4.87%

Jul. 01	Buchang Pharmaceuticals' Unit Gets Registration Certificate for Lacosamide Injection	MT
Jun. 20	Shandong Buchang Pharmaceuticals Co., Ltd. agreed to acquire an additional 8.50% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) for CNY 0.	CI

Shandong Buchang Pharmaceuticals Gets Marketing Approval for Arthritis, Psoriasis Drug

Published on 06/11/2025 at 03:39

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Shandong Buchang Pharmaceuticals Co., Ltd.

Buchang Pharmaceuticals' Unit Gets Registration Certificate for Lacosamide Injection	Jul. 01	MT
Shandong Buchang Pharmaceuticals Co., Ltd. agreed to acquire an additional 8.50% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) for CNY 0.	Jun. 20	CI
Shandong Buchang Pharmaceuticals Gets Marketing Approval for Arthritis, Psoriasis Drug	Jun. 11	MT
Buchang Pharmaceuticals' Unit Withdraws Clinical Application for Rabies Vaccine	Jun. 04	MT
Workshops of Buchang Pharmaceuticals' Unit Passes GMP Standards	May. 28	MT
Buchang Pharmaceuticals Amends Warehouse Addresses in License	May. 28	MT
Buchang Pharmaceuticals' Unit Gets Registration Certificate for Besilate Atracurium Injection	May. 28	MT
Shareholder to Offload Stake in Buchang Pharmaceuticals Unit	May. 27	MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 27, 2024.	May. 09	CI
Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback announced on December 27, 2024 has closed with of 6,620,630 shares, representing 0.62% for CNY 98.06 million.	May. 08	CI
Buchang Pharma's Unit Gets Nod to Amend Manufacturing License	May. 05	MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	Apr. 25	CI
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 27, 2024.	Apr. 01	CI
Buchang Pharmaceuticals Gets Approval for Rabies Vaccine Clinical Trial	Mar. 12	MT
Buchang Pharmaceuticals Gets Approval for Chickenpox Vaccine Clinical Trial	Mar. 12	MT
Shandong Buchang Pharmaceuticals Gets Regulatory Approval for Drug Manufacturing License Changes	Feb. 20	MT
Buchang Pharmaceuticals Subsidiary Completes Industrial, Commercial Registration	Feb. 14	MT
Buchang Pharma Unit Gets China Clinical Trial Approval for Colon Cleansing Tablets	Feb. 11	MT
Shandong Buchang Pharmaceuticals Dissolves Unit	Feb. 10	MT
Buchang Pharmaceuticals Subsidiary Passes GMP Inspection for Danhong Injection	Feb. 07	MT
Shandong Buchang Pharmaceuticals Makes Changes to Drug Production License	Jan. 28	MT
Buchang Pharma's Unit Gets Approval to Market Oseltamivir Phosphate Dry Suspension	Jan. 09	MT
Buchang Pharmaceuticals to Set Up Medical Equipment Subsidiary	Jan. 09	MT
Shandong Buchang Pharmaceuticals Terminates Agreements With Nantong Lianya Pharmaceutical	Dec. 26	MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	Dec. 26	CI

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

Duration

Period

Chart Shandong Buchang Pharmaceuticals Co., Ltd.

603858: Dynamic Chart

SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Companyâs main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.

Employees

7,689

Sector

Pharmaceuticals

Calendar

Aug. 27 - Q2 2025 Earnings Release

More about the company